Butyl 2-chloroacetate | CAS:590-02-3

We serve Butyl 2-chloroacetate CAS:590-02-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Butyl 2-chloroacetate

Synonyms:
Acetic acid,chloro-,butyl ester
n-Butyl-chloroacetate
1-butyl chloroacetate
butyl monochloroacetate
Acetic acid, chloro-, butyl ester
n-butyl monochloroacetate
chloroacetic acid n-butyl ester
butyl chloroacetate
 
Molecular Formula:  C6H11ClO2
Molecular Weight:  150.60300
 
 
Density: 1,07 g/cm3
Boiling point: 72 °C
Refractive index: 1.425
 
Applications: Organic synthesis.

Items of Analysis Standard of Analysis Test Results
Appearance Colorless transparent liquid Conform
Purity ≥98.5% 98.9%
Moisture ≤0.5% 0.07%
Conclusion Conforms to Factory Standard
 



Contact us for information like Butyl 2-chloroacetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,butyl chloroacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acetic acid,chloro-,butyl ester Use and application,Butyl 2-chloroacetate technical grade,usp/ep/jp grade.


Related News: It also said it would bar South Koreans from visiting China as tourists.spiro[indan-2,2′-naphthalene]-1,3,1′,3′,4′-pentaone manufacturer If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.Peptide,(Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Xaa-Glu-Xaa-Xaa-Gly-Xaa-Xaa-Xaa-Pro-Arg-Val-Xaa-Xaa-Arg) supplier If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.1-(benzoyl-methyl-amino)-7-methyl-imidazo[1,5-a]pyrazine-6,8-dione vendor If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.